nab-paclitaxel (nab-P) plus nivolumab (Nivo) ± gemcitabine (Gem) in patients (pts) with advanced pancreatic cancer (PC).

被引：6
|
作者：
Firdaus, Irfan
Waterhouse, David Michael
Gutierrez, Martin
Wainberg, Zev A.
George, Ben
Kelly, Karen
Bekaii-Saab, Tanios S.
Carrizosa, Daniel R.
Soliman, Hatem Hussein
Fraser, Cindy Duval
Ko, Amy
Pierce, Daniel W.
Manax, Victoria G.
Stergiopoulos, Sotirios G.
Hochster, Howard S.
机构：
[1] Oncol Hematol Care Inc, Sarah Cannon Res Inst, Cincinnati, OH USA
[2] OHC Oncol Hematol Care, Blue Ash, OH USA
[3] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA
[4] Ronald Regan UCLA Med Ctr, Los Angeles, CA USA
[5] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[6] UC Davis Comprehens Canc Ctr, Sacramento, CA USA
[7] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[8] Levine Canc Inst, Charlotte, NC USA
[9] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[10] Celgene Corp, Summit, NJ USA
[11] Celgene Corp, Great Neck, NY USA
[12] Yale Univ, Sch Med, Dept Med Oncol, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.tps475
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS475
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine (nab-P/G) vs FOLFIRINOX (FFX) in patients (pts) with advanced pancreatic cancer (aPC)
    Chiorean, E. G.
    Cheung, W. Y.
    Giordano, G.
    Kim, G.
    Al-Batran, S-E.
    ANNALS OF ONCOLOGY, 2018, 29 : 245 - 246
  • [22] Phase I study of nivolumab (nivo) plus nab-paclitaxel (nab-P) plus carboplatin (C) in advanced NSCLC: safety and efficacy results
    Waterhouse, David M.
    George, Ben
    Gutierrez, Martin
    Otterson, Greg A.
    Ko, Amy
    Ong, Teng Jin
    Stergiopoulos, Sotirios
    Trunova, Nataliya
    Kelly, Karen
    CANCER RESEARCH, 2016, 76
  • [23] Efficacy and safety of nab-paclitaxel plus S-1(nab-P/S-1) versus nab-paclitaxel plus gemcitabine (nab-P/Gem) for first-line chemotherapy in advanced pancreatic ductal adenocarcinoma (aPDAC): A randomized study
    Zong, Yuan
    Peng, Zhi
    Wang, Xicheng
    Shen, Lin
    Zhou, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [24] The international, open-label, multicenter phase 2 LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) for patients with locally advanced pancreatic cancer (LAPC)
    Pascal, Hammel
    Jill, Lacy
    Fabienne, Portales
    Alberto, Sobrero
    Beatriz, Garca-Paredes
    Edward, Kim
    Fernando, Rivera
    Jose Luis, Manzano
    Eric, Terrebonne
    Venu, Bathini
    Scot, Dowden
    Jamil, Asselah
    Jack, Shiansong Li
    Thomas, Nydam
    Louis, Kayitalire
    Philip, Philip
    ANNALS OF ONCOLOGY, 2016, 27 : 78 - 79
  • [25] FOLFOX and nab-paclitaxel (nab-P) for advanced pancreatic cancer: A phase I study
    Safran, Howard
    Charpentier, Kevin
    Perez, Kimberly
    Mantripragada, Kalyan
    Austin, Trevor Clark
    Nadeem, Omar
    Lombardo, Alise
    Houlihan, Lindsay
    Fontes-Borts, Lucia
    Kolberg, Irene
    Mitchell, Kristen
    Rosati, Kayla
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [26] HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P plus GEM) for unresectable locally advanced pancreatic cancer (LAPC)
    Tanimoto, A.
    Yagisawa, M.
    Nakano, S.
    Kawamoto, Y.
    Yuki, S.
    Ishiguro, A.
    Takahata, T.
    Sato, A.
    Iwanaga, I.
    Ehira, N.
    Uebayashi, M.
    Muto, O.
    Sasaki, T.
    Hatanaka, K.
    Tateyama, M.
    Wakabayashi, T.
    Dazai, M.
    Minami, S.
    Sakata, Y.
    Komatsu, Y.
    ANNALS OF ONCOLOGY, 2019, 30
  • [27] Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P plus Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival
    Tempero, M.
    O'Reilly, E.
    Van Cutsem, E.
    Berlin, J.
    Philip, P.
    Goldstein, D.
    Tabernero, J.
    Borad, M.
    Bachet, J.
    Parner, V.
    Tebbutt, N.
    Chua, Y.
    Corrie, P.
    Harris, M.
    Taieb, J.
    Burge, M.
    Kunzmann, V.
    Zhang, G.
    McGovern, D.
    Marks, H.
    Biankin, A.
    Reni, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S226 - S226
  • [28] Gemcitabine (G) plus nab-paclitaxel (nab-P) versus G in patients (pts) with advanced pancreatic cancer (PDAC) after FOLFIRINOX: A single center, retrospective review.
    Chan, Edmond Mankee
    Hong, Theodore S.
    Clark, Jeffrey William
    Blaszkowsky, Lawrence Scott
    Allen, Jill N.
    Zhu, Andrew
    Goyal, Lipika
    Murphy, Janet E.
    Kwak, Eunice L.
    Wo, Jennifer Y.
    Ryan, David P.
    Faris, Jason Edward
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [29] SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study
    Von Hoff, D. D.
    Ramanathan, R.
    Borad, M.
    Laheru, D.
    Smith, L.
    Wood, T.
    Korn, R.
    Desai, N.
    Iglesias, J.
    Hidalgo, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] Predictors of vulnerability to nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer
    Iede, Kiyotsugu
    Yamada, Terumasa
    Tominaga, Shusei
    ANNALS OF ONCOLOGY, 2023, 34 : S1453 - S1453
12345